Post by icemandios on Feb 2, 2023 13:37:01 GMT
Xeris Biopharma to Participate in the SVB Securities Global Biopharma Conference 2023
Xeris Biopharma, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will hold 1x1 investor meetings and present an overview of the Company at the SVB Securities Global Biopharma Conference 2023, which is taking place in a virtual format.
Presentation Date: Wednesday, February 15, 2023
Time: 10:40 am – 11:10 am. ET
An audio webcast of the presentation can be accessed by visiting ‘Upcoming Events’ in the Investors section on the Company's website at www.xerispharma.com .
wsw.com/webcast/svb8/xers/1643814
About Xeris
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis®, the first FDA-approved therapy for primary periodic paralysis; and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris also has an increasingly diverse pipeline of development and partnered programs using its proprietary formulation technology platforms, XeriSol™ and XeriJect™, bringing new products forward for the company as well as its partners.
Xeris Biopharma, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will hold 1x1 investor meetings and present an overview of the Company at the SVB Securities Global Biopharma Conference 2023, which is taking place in a virtual format.
Presentation Date: Wednesday, February 15, 2023
Time: 10:40 am – 11:10 am. ET
An audio webcast of the presentation can be accessed by visiting ‘Upcoming Events’ in the Investors section on the Company's website at www.xerispharma.com .
wsw.com/webcast/svb8/xers/1643814
About Xeris
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis®, the first FDA-approved therapy for primary periodic paralysis; and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris also has an increasingly diverse pipeline of development and partnered programs using its proprietary formulation technology platforms, XeriSol™ and XeriJect™, bringing new products forward for the company as well as its partners.